Published in Am J Med Genet on May 15, 2000
ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell (2012) 1.18
Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis (2012) 1.17
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One (2012) 1.13
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol (2014) 0.89
Dissecting the clinical phenotype associated with mosaic type-2 NF1 microdeletions. Neurogenetics (2012) 0.83
Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI. Eur J Med Res (2010) 0.82
Malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1. Case Rep Oncol Med (2014) 0.78
Solitary plexiform neurofibroma, a pitfall in diagnosis of lipoma. BMJ Case Rep (2010) 0.75
Extensive plexiform neurofibroma in a premature neonate. Clin Med Res (2014) 0.75
Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet (2017) 0.75
Sarcomas in children with neurofibromatosis type 1-poor prognosis despite aggressive combined therapy in four patients treated in a single oncological institution. Childs Nerv Syst (2007) 0.75
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation (1996) 2.70
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Loss-of-function mutations in the EGF-CFC gene CFC1 are associated with human left-right laterality defects. Nat Genet (2000) 1.92
Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet (2000) 1.76
Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS (2001) 1.48
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43
A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol (1993) 1.43
Pulmonary aspergillosis in a child with hyperimmunoglobulin E syndrome. Clin Infect Dis (1998) 1.41
Complementary DNA probes for the Duchenne muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. J Clin Invest (1989) 1.30
Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29
Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet (2000) 1.27
Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol (2007) 1.22
Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol (2001) 1.21
Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res (1998) 1.21
Eosinophilic cystitis in a 4-year-old boy: successful long-term treatment with cyclosporin A. Pediatrics (2001) 1.18
Porin interaction with hexokinase and glycerol kinase: metabolic microcompartmentation at the outer mitochondrial membrane. Biochem Med Metab Biol (1991) 1.18
Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology (2004) 1.17
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol (2001) 1.16
Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol (2000) 1.16
Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2007) 1.14
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14
Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology (2006) 1.09
The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol (2001) 1.08
Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans. Am J Hum Genet (2007) 1.06
Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene (2011) 1.05
Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis (1995) 1.02
Localization of gene for familial hypertrophic cardiomyopathy to chromosome 14q1 in a diverse US population. Circulation (1991) 1.02
PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum Mutat (2002) 1.02
Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia (2001) 0.99
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet (1993) 0.99
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol (2009) 0.97
Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med (2001) 0.97
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96
Predicting outcome after listing for heart transplantation in children: comparison of Kaplan-Meier and parametric competing risk analysis. Pediatric Heart Transplant Study Group. J Heart Lung Transplant (1997) 0.95
miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene (2012) 0.95
The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology (2006) 0.95
Ezrin, radixin, and moesin are components of Schwann cell microvilli. J Neurosci Res (2001) 0.94
Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res (1997) 0.94
Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J Neurosci Res (1996) 0.94
Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene (2006) 0.93
Prevalence of viral DNA in amniotic fluid of low-risk pregnancies in the second trimester. J Matern Fetal Neonatal Med (2003) 0.93
Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett (1996) 0.93
Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol (2009) 0.92
The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. Cell Growth Differ (1995) 0.92
Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond) (2011) 0.89
Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online. Hum Mutat (1998) 0.88
The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet (2000) 0.88
Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene (2010) 0.87
Molecular analysis of malignant triton tumors. Hum Pathol (1999) 0.87
Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. Oncogene (1994) 0.87
Merlin: hanging tumor suppression on the Rac. Trends Cell Biol (2001) 0.87
Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol (1999) 0.86
Osteochondritis dissecans of the tibial plateau. A case report. J Bone Joint Surg Am (1982) 0.86
Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci (1998) 0.85
The ecology of brain tumors: lessons learned from neurofibromatosis-1. Oncogene (2010) 0.85
Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology (2006) 0.83
Overexpression of bax in human glioma cell lines. J Neurosurg (1999) 0.83
Evidence of genetic heterogeneity in the long QT syndrome. Science (1993) 0.83
Characterization and expression of H-21 region gene products on bone marrow-derived macrophages. Eur J Immunol (1982) 0.83
Expression of the neurofibromatosis 1 (NF1) gene during growth arrest. Neuroreport (1996) 0.82
"Unresolving pneumonia" as the main manifestation of atypical Kawasaki disease. Arch Dis Child (2003) 0.81
Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. Neuropathol Appl Neurobiol (2011) 0.81
Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. Am J Med Genet (1995) 0.81
Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol (1997) 0.81
Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. Neurobiol Dis (1996) 0.81
Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. Neuroreport (1995) 0.80
Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet (2000) 0.80
Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J Neurosci Res (1996) 0.80
Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol (1996) 0.80
Integrated MR imaging and proton nuclear magnetic resonance spectroscopy in a family with an X-linked spastic paraparesis. AJNR Am J Neuroradiol (1991) 0.80
Maturation of the heart. Clin Perinatol (1988) 0.79
An alternative apnea test for the evaluation of brain death. Ann Neurol (1991) 0.79
Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dyn (2004) 0.79
The question of familial meningiomas and schwannomas: NF2B or not to be? Neurology (2000) 0.79
Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. Arch Dermatol (1996) 0.79
Neurofibromatosis 2 and malignant mesothelioma. Neurology (2002) 0.79
Major histocompatibility complex regulation of the immune response. J Surg Res (1985) 0.79
Ammonium acetate protocol for the preparation of plasmid DNA suitable for mammalian cell transfections. Biotechniques (1997) 0.78
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. Neurosurg Focus (1997) 0.78
Chromosome 11q23.3-qter deletion and Alexander disease. Am J Med Genet (1991) 0.78
Learning disabilities in neurofibromatosis 1: sizing up the brain. Arch Neurol (1999) 0.78
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg (1998) 0.77
Isolation of a de novo mutant myocardial beta MHC protein in a pedigree with hypertrophic cardiomyopathy. Hum Mol Genet (1994) 0.77
Tolerance to experimental contact sensitivity induced by T cell vaccination. Eur J Immunol (1990) 0.77
Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. Neuropathol Appl Neurobiol (2012) 0.76
In-vitro-derived bone marrow macrophages. Expression of Ia antigens during macrophage differentiation. Transplantation (1984) 0.76
Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Fam Cancer (2012) 0.76
Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell. Am J Pathol (1994) 0.76
Tumor suppressor gene regulation of cell growth: recent insights into neurofibromatosis 1 and 2 gene function. Cell Biochem Biophys (2001) 0.76
Prevention of human immunodeficiency virus mother-to-child transmission in Israel. Int J STD AIDS (2009) 0.75